Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

2.1 Sotorasib (Lumykras, Amgen) is indicated 'as monotherapy for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC), who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti‑PD‑1/PD‑L1 immunotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for sotorasib.

2.3 The anticipated list price of sotorasib is £6,907.35 for a 30‑day supply of 240 tablets, each containing 120 mg (excluding VAT, company submission). The company has a commercial arrangement (managed access agreement including a commercial access agreement). This makes sotorasib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.